follicular lymphoma foundation
follicular lymphoma foundation Company Information
Company Number
11943477
Next Accounts
Sep 2025
Shareholders
-
Group Structure
View All
Industry
Other human health activities
Registered Address
new derwent house, 69-73 theobalds road, london, WC1X 8TA
Website
https://www.theflf.orgfollicular lymphoma foundation Estimated Valuation
Pomanda estimates the enterprise value of FOLLICULAR LYMPHOMA FOUNDATION at £1m based on a Turnover of £2.1m and 0.5x industry multiple (adjusted for size and gross margin).
follicular lymphoma foundation Estimated Valuation
Pomanda estimates the enterprise value of FOLLICULAR LYMPHOMA FOUNDATION at £201.3k based on an EBITDA of £51.8k and a 3.89x industry multiple (adjusted for size and gross margin).
follicular lymphoma foundation Estimated Valuation
Pomanda estimates the enterprise value of FOLLICULAR LYMPHOMA FOUNDATION at £3m based on Net Assets of £1.3m and 2.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Follicular Lymphoma Foundation Overview
Follicular Lymphoma Foundation is a live company located in london, WC1X 8TA with a Companies House number of 11943477. It operates in the other human health activities sector, SIC Code 86900. Founded in April 2019, it's largest shareholder is unknown. Follicular Lymphoma Foundation is a young, small sized company, Pomanda has estimated its turnover at £2.1m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Follicular Lymphoma Foundation Health Check
Pomanda's financial health check has awarded Follicular Lymphoma Foundation a 5 rating. We use a traffic light system to show it exceeds the industry average on 8 measures and has 2 areas for improvement. Company Health Check FAQs
8 Strong
1 Regular
2 Weak
Size
annual sales of £2.1m, make it larger than the average company (£796.3k)
£2.1m - Follicular Lymphoma Foundation
£796.3k - Industry AVG
Growth
3 year (CAGR) sales growth of 76%, show it is growing at a faster rate (6.5%)
76% - Follicular Lymphoma Foundation
6.5% - Industry AVG
Production
with a gross margin of 36.5%, this company has a comparable cost of product (36.5%)
36.5% - Follicular Lymphoma Foundation
36.5% - Industry AVG
Profitability
an operating margin of 2.4% make it less profitable than the average company (5.5%)
2.4% - Follicular Lymphoma Foundation
5.5% - Industry AVG
Employees
with 7 employees, this is below the industry average (19)
7 - Follicular Lymphoma Foundation
19 - Industry AVG
Pay Structure
on an average salary of £16.6k, the company has a lower pay structure (£26.9k)
£16.6k - Follicular Lymphoma Foundation
£26.9k - Industry AVG
Efficiency
resulting in sales per employee of £295.5k, this is more efficient (£51.3k)
£295.5k - Follicular Lymphoma Foundation
£51.3k - Industry AVG
Debtor Days
it gets paid by customers after 12 days, this is earlier than average (22 days)
12 days - Follicular Lymphoma Foundation
22 days - Industry AVG
Creditor Days
its suppliers are paid after 20 days, this is slower than average (17 days)
20 days - Follicular Lymphoma Foundation
17 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Follicular Lymphoma Foundation
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 598 weeks, this is more cash available to meet short term requirements (102 weeks)
598 weeks - Follicular Lymphoma Foundation
102 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 8.1%, this is a lower level of debt than the average (27.9%)
8.1% - Follicular Lymphoma Foundation
27.9% - Industry AVG
FOLLICULAR LYMPHOMA FOUNDATION financials
Follicular Lymphoma Foundation's latest turnover from December 2023 is £2.1 million and the company has net assets of £1.3 million. According to their latest financial statements, Follicular Lymphoma Foundation has 7 employees and maintains cash reserves of £1.3 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Apr 2020 | |
|---|---|---|---|---|---|
| Turnover | 2,068,654 | 2,186,258 | 1,678,822 | 380,322 | 502,971 |
| Other Income Or Grants | |||||
| Cost Of Sales | |||||
| Gross Profit | |||||
| Admin Expenses | |||||
| Operating Profit | |||||
| Interest Payable | |||||
| Interest Receivable | |||||
| Pre-Tax Profit | 88,834 | -223,905 | 1,043,088 | 91,895 | 264,441 |
| Tax | |||||
| Profit After Tax | 88,834 | -223,905 | 1,043,088 | 91,895 | 264,441 |
| Dividends Paid | |||||
| Retained Profit | 88,834 | -223,905 | 1,043,088 | 91,895 | 264,441 |
| Employee Costs | 116,082 | 86,929 | 37,023 | 12,558 | 24,148 |
| Number Of Employees | 7 | 5 | 4 | 1 | 1 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Apr 2020 | |
|---|---|---|---|---|---|
| Tangible Assets | 4,999 | 7,033 | 5,696 | 2,627 | 839 |
| Intangible Assets | |||||
| Investments & Other | |||||
| Debtors (Due After 1 year) | |||||
| Total Fixed Assets | 4,999 | 7,033 | 5,696 | 2,627 | 839 |
| Stock & work in progress | |||||
| Trade Debtors | 73,256 | 50,000 | |||
| Group Debtors | |||||
| Misc Debtors | 10,590 | 7,766 | 22,775 | 9,911 | 9,714 |
| Cash | 1,287,372 | 1,381,442 | 1,416,474 | 508,176 | 311,181 |
| misc current assets | |||||
| total current assets | 1,371,218 | 1,439,208 | 1,439,249 | 518,087 | 320,895 |
| total assets | 1,376,217 | 1,446,241 | 1,444,945 | 520,714 | 321,734 |
| Bank overdraft | |||||
| Bank loan | 16,401 | ||||
| Trade Creditors | 72,972 | 211,984 | 14,633 | 2,858 | 7,756 |
| Group/Directors Accounts | |||||
| other short term finances | |||||
| hp & lease commitments | |||||
| other current liabilities | 38,891 | 42,336 | 30,887 | 161,520 | 49,537 |
| total current liabilities | 111,863 | 270,721 | 45,520 | 164,378 | 57,293 |
| loans | |||||
| hp & lease commitments | |||||
| Accruals and Deferred Income | |||||
| other liabilities | |||||
| provisions | |||||
| total long term liabilities | |||||
| total liabilities | 111,863 | 270,721 | 45,520 | 164,378 | 57,293 |
| net assets | 1,264,354 | 1,175,520 | 1,399,425 | 356,336 | 264,441 |
| total shareholders funds | 1,264,354 | 1,175,520 | 1,399,425 | 356,336 | 264,441 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Apr 2020 | |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Operating Profit | |||||
| Depreciation | 2,482 | 3,263 | 2,578 | 1,522 | 420 |
| Amortisation | |||||
| Tax | |||||
| Stock | |||||
| Debtors | 26,080 | 34,991 | 12,864 | 9,911 | 9,714 |
| Creditors | -139,012 | 197,351 | 11,775 | 2,858 | 7,756 |
| Accruals and Deferred Income | -3,445 | 11,449 | -130,633 | 161,520 | 49,537 |
| Deferred Taxes & Provisions | |||||
| Cash flow from operations | |||||
| Investing Activities | |||||
| capital expenditure | |||||
| Change in Investments | |||||
| cash flow from investments | |||||
| Financing Activities | |||||
| Bank loans | -16,401 | 16,401 | |||
| Group/Directors Accounts | |||||
| Other Short Term Loans | |||||
| Long term loans | |||||
| Hire Purchase and Lease Commitments | |||||
| other long term liabilities | |||||
| share issue | |||||
| interest | |||||
| cash flow from financing | -16,401 | 16,401 | 1 | 264,441 | |
| cash and cash equivalents | |||||
| cash | -94,070 | -35,032 | 908,298 | 508,176 | 311,181 |
| overdraft | |||||
| change in cash | -94,070 | -35,032 | 908,298 | 508,176 | 311,181 |
follicular lymphoma foundation Credit Report and Business Information
Follicular Lymphoma Foundation Competitor Analysis
Perform a competitor analysis for follicular lymphoma foundation by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other small companies, companies in WC1X area or any other competitors across 12 key performance metrics.
follicular lymphoma foundation Ownership
FOLLICULAR LYMPHOMA FOUNDATION group structure
Follicular Lymphoma Foundation has no subsidiary companies.
Ultimate parent company
FOLLICULAR LYMPHOMA FOUNDATION
11943477
follicular lymphoma foundation directors
Follicular Lymphoma Foundation currently has 9 directors. The longest serving directors include Lord Jonathan Mendelsohn (Apr 2019) and Lady Nicola Mendelsohn (Apr 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Lord Jonathan Mendelsohn | England | 58 years | Apr 2019 | - | Director |
| Lady Nicola Mendelsohn | 53 years | Apr 2019 | - | Director | |
| Lord Jonathan Mendelsohn | England | 58 years | Apr 2019 | - | Director |
| Lord Richard Harrington | 67 years | Jun 2019 | - | Director | |
| Miss Andrea Wong | England | 58 years | Aug 2019 | - | Director |
| Mr Peter Thompson | United Kingdom | 67 years | Feb 2020 | - | Director |
| Mr Jonathan Simons | England | 66 years | Jul 2022 | - | Director |
| Mrs Jessica Burley | England | 59 years | Jul 2022 | - | Director |
| Ms Katherine Rogers | 59 years | Jul 2022 | - | Director |
P&L
December 2023turnover
2.1m
-5%
operating profit
49.3k
0%
gross margin
36.6%
+0.46%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
1.3m
+0.08%
total assets
1.4m
-0.05%
cash
1.3m
-0.07%
net assets
Total assets minus all liabilities
follicular lymphoma foundation company details
company number
11943477
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
April 2019
age
6
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
COOPER PARRY GROUP LIMITED
address
new derwent house, 69-73 theobalds road, london, WC1X 8TA
Bank
-
Legal Advisor
-
follicular lymphoma foundation Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to follicular lymphoma foundation.
follicular lymphoma foundation Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for FOLLICULAR LYMPHOMA FOUNDATION. This can take several minutes, an email will notify you when this has completed.
follicular lymphoma foundation Companies House Filings - See Documents
| date | description | view/download |
|---|
